Shares of Bavarian Nordic jumped more than 20 percent this morning after the company reported that the FDA had raised a green flag for the production and delivery of its smallpox vaccine Imvamune. Analysts cheered the move as a major event for the biopharma company. "This represents a transformational step in the company lifecycle of Bavarian Nordic from being a developmental, R&D focused company to an order producing pharmaceutical business," S&P says in a note. Bavarian release | Report